Approved Marketing Authorisations (MA) of Tiefenbacher in Europe aggregated by PharmaCompass

PharmaCompass
Related CompaniesRelated Companies

About

Founded in 1963 as the world’s first exclusive agency for APIs, the Tiefenbacher Group has evolved into a leading healthcare company offering innovative solutions across the entire pharmaceutical value chain. Tiefenbacher distributes raw materials and excels in the development, manufacture and registration of FDFs, including tablets, capsules, powders, drops, patches and medical devices. Tiefenbacher offers integrated services like pharmaceutical distribution, supply chain management, contract manufacturing, regulatory consulting and market access support. It aims to provide affordable, high-quality healthcare solutions worldwide.

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Van-der-Smissen-Strasse 1, 22767 Hamburg
Telephone
Telephone
+49 404418090
Twitter
Twitter
Contact Info
Others

Events

Webinars & Exhibitions

CPhI Worldwide, Milan

CPhI Worldwide, Milan

Not Confirmed

envelop Contact Supplier

CPhI Worldwide, Milan

Post an Enquiry

Meeting

Digital content read-more

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-21386.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-26459.pdf

    https://www.pharmacompass.com/pdf/party/content/tiefenbacher-group-party-content-7484.pdf

NEWS #PharmaBuzz

read-more
read-more

https://tiefenbacher-pharmaceuticals.com/2024/05/02/tiefenbacher-group-renovation-of-headquarters-in-hamburg/

PRESS RELEASE
02 May 2024

https://tiefenbacher-pharmaceuticals.com/2024/04/09/tiefenbacher-first-to-market-launch-rivaroxaban/

PRESS RELEASE
09 Apr 2024

https://tiefenbacher-pharmaceuticals.com/2024/04/08/tiefenbacher-group-welcomes-new-coo-sandip-tarate/

PRESS RELEASE
08 Apr 2024

https://tiefenbacher-pharmaceuticals.com/2024/03/19/tiefenbacher-group-awarded-ecovadis-silver-medal/

PRESS RELEASE
19 Mar 2024

https://tiefenbacher-pharmaceuticals.com/2024/02/29/tiefenbacher-group-on-awareness-for-rare-disease-day/

PRESS RELEASE
29 Feb 2024

https://tiefenbacher-pharmaceuticals.com/2024/02/14/tiefenbacher-group-renovation-of-headquarters/

PRESS RELEASE
14 Feb 2024

Drugs in Development

read-more
read-more

Details:

Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


Lead Product(s): Rivaroxaban

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 09, 2024

Tiefenbacher Compnay Banner

01

Boulder Peptide 2024
Not Confirmed

Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

Product Name : Xarelto-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

April 09, 2024

Tiefenbacher Compnay Banner

Details:

Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


Lead Product(s): Rivaroxaban

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 16, 2023

Tiefenbacher Compnay Banner

02

Boulder Peptide 2024
Not Confirmed

Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

Product Name : Xarelto-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

November 16, 2023

Tiefenbacher Compnay Banner

Details:

Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.


Lead Product(s): Teriflunomide

Therapeutic Area: Neurology Product Name: Aubagio-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 27, 2023

Tiefenbacher Compnay Banner

03

Boulder Peptide 2024
Not Confirmed

Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Product Name : Aubagio-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

September 27, 2023

Tiefenbacher Compnay Banner

Details:

Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.


Lead Product(s): Bilastine

Therapeutic Area: Immunology Product Name: Bilastine Tiefenbacher

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 14, 2023

Tiefenbacher Compnay Banner

04

Boulder Peptide 2024
Not Confirmed

Details : Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.

Product Name : Bilastine Tiefenbacher

Product Type : Small molecule

Upfront Cash : Not Applicable

March 14, 2023

Tiefenbacher Compnay Banner

Details:

Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.


Lead Product(s): Apremilast

Therapeutic Area: Dermatology Product Name: Otezla-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 01, 2022

Tiefenbacher Compnay Banner

05

Boulder Peptide 2024
Not Confirmed

Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulce...

Product Name : Otezla-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

December 01, 2022

Tiefenbacher Compnay Banner

Details:

Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.


Lead Product(s): Abiraterone Acetate,Prednisolone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 17, 2022

Tiefenbacher Compnay Banner

06

Boulder Peptide 2024
Not Confirmed

Details : Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe ...

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

November 17, 2022

Tiefenbacher Compnay Banner

Details:

Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.


Lead Product(s): Apixaban

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Apixaban Tiefenbacher

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 20, 2022

Tiefenbacher Compnay Banner

07

Boulder Peptide 2024
Not Confirmed

Details : Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Product Name : Apixaban Tiefenbacher

Product Type : Small molecule

Upfront Cash : Not Applicable

October 20, 2022

Tiefenbacher Compnay Banner

Details:

Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.


Lead Product(s): Vildagliptin,Metformin

Therapeutic Area: Endocrinology Product Name: Vildagliptin-Metformin-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 08, 2022

Tiefenbacher Compnay Banner

08

Boulder Peptide 2024
Not Confirmed

Details : Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.

Product Name : Vildagliptin-Metformin-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

September 08, 2022

Tiefenbacher Compnay Banner

Details:

Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.


Lead Product(s): Rivaroxaban

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2022

Tiefenbacher Compnay Banner

09

Boulder Peptide 2024
Not Confirmed

Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

Product Name : Xarelto-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

July 15, 2022

Tiefenbacher Compnay Banner

Details:

Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.


Lead Product(s): Teriflunomide

Therapeutic Area: Immunology Product Name: Teriflunomide-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

Tiefenbacher Compnay Banner

10

Boulder Peptide 2024
Not Confirmed

Details : Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.

Product Name : Teriflunomide-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

June 01, 2022

Tiefenbacher Compnay Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Check the inspections & registration from this company

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty